Amgen (AMGN)
Health Care · Biopharmaceuticals / Biologics · NASDAQ
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures.
What Amgen does
Amgen is a multinational biopharmaceutical company that develops, manufactures, and markets human therapeutics across oncology, cardiovascular disease, inflammation, bone health, neuroscience, and other therapeutic areas. The company operates through a portfolio of branded biologic and small-molecule drugs distributed globally, with significant revenue exposure to the U.S. Medicare market. Amgen engages in research and development of novel therapeutics, including gene therapies and monoclonal antibodies, while managing manufacturing and supply chains for marketed products. The company is subject to evolving U.S. government drug pricing regulations, including mandatory Medicare price negotiation and Most-Favored-Nations pricing directives.
Themes: ["Oncology / cancer therapeutics","Cardiovascular disease","Inflammation and immunology","Bone health / osteoporosis","GLP-1 / metabolic disease","Biosimilars","Monoclonal antibodies","Medicare price negotiation","Drug pricing regulation","Gene therapy / advanced biologics"]
Fundamentals
- Price$363.62 as of 2026-07-09 close
- Market cap$198.6B as of 2026-07-10
- 1-year return+22.6% as of 2026-07-09 close
- P/E25.46 as of 2026-07-10
- Net margin+21.0% as of 2026-07-10
- Gross margin+74.0% as of 2026-07-10
- ROE+89.4% as of 2026-07-10
- Debt / equity6.24 as of 2026-07-10
- Revenue growth (YoY)+9.1% as of 2026-07-10
- Revenue CAGR (3y)+11.8% SEC XBRL
- Beta0.43 as of 2026-07-10
Dividend: yield +2.7%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Exposure to U.S. Medicare drug price negotiation under the Inflation Reduction Act, with multiple products subject to price setting and ongoing regulatory changes creating uncertainty in reimbursement and revenue","Most-Favored-Nations pricing directives and state-level pricing initiatives requiring pricing alignment with international markets and disclosure of proprietary pricing data, risking price erosion and compliance penalties","Patent expirations and biosimilar competition for key revenue drivers (ENBREL, Otezla, and others), combined with increased generic/biosimilar substitution flexibility in Medicare Part D plans"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.